IDEXX Laboratories Inc (IDXX)
IDEXX Laboratories Inc (IDXX) carries a ŷRobot AI score of 64 out of 100. The model's fair value estimate is $751.00, 6.6% above the last close of $704.23. The chart signal reads Sell.
| Metric | IDXX |
|---|---|
| AI score | 64 / 100 |
| Chart signal | Sell |
| Fair value estimate | $751.00 |
| Upside to fair value | 6.6% |
| Previous close | $704.23 |
| P/E | 38.73 |
| Price / sales | 11.63 |
| Market cap | $55.35B |
| EPS | 17.34 |
| Revenue growth | 8.0% |
| 1-year price change | -7.1% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about IDXX
Is IDXX overvalued or undervalued right now?
As of Nov 4, 2026, ŷRobot's fair-value model estimates IDEXX Laboratories Inc (IDXX) at $751.00 against a last close of $704.23, implying 6.6% upside to the model's estimate.
Is IDXX's chart signal bullish or bearish?
The chart-signal model classifies IDXX as Neutral as of Nov 13, 2026, with a signal score of -0.13 on a -1 to 1 scale.
What is IDXX's ŷRobot AI score?
IDXX scores 64 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is IDXX stock expensive on P/E and P/S?
IDXX trades at 38.7 times earnings and 11.6 times sales as of Nov 13, 2026.
What does IDXX's seasonal forecast show?
ŷRobot's seasonal forecast curve for IDXX reads +0.4% at 30 days, +0.3% at 90 days, and -7.1% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is IDXX growing?
IDEXX Laboratories Inc's revenue growth is +8.0% and free-cash-flow growth is +5.0% on the latest reported figures.
IDXX chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.